Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb.

Jansma AL, Martinez-Yamout MA, Liao R, Sun P, Dyson HJ, Wright PE.

J Mol Biol. 2014 Dec 12;426(24):4030-4048. doi: 10.1016/j.jmb.2014.10.021. Epub 2014 Nov 1.

2.

Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein.

Ferreon JC, Martinez-Yamout MA, Dyson HJ, Wright PE.

Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13260-5. doi: 10.1073/pnas.0906770106. Epub 2009 Jul 27.

3.

The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein.

Wang J, Zhou D, Prabhu A, Schlegel R, Yuan H.

PLoS Pathog. 2010 Sep 2;6(9):e1001089. doi: 10.1371/journal.ppat.1001089.

4.

Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor.

Liu X, Clements A, Zhao K, Marmorstein R.

J Biol Chem. 2006 Jan 6;281(1):578-86. Epub 2005 Oct 24.

5.
6.

Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.

Jenkins LM, Yamaguchi H, Hayashi R, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, Mazur SJ.

Biochemistry. 2009 Feb 17;48(6):1244-55. doi: 10.1021/bi801716h.

7.

Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression.

Morandell D, Rostek U, Bouvard V, Campo-Fernández B, Fiedler M, Jansen-Dürr P, Zwerschke W.

Virology. 2008 Sep 15;379(1):20-9. doi: 10.1016/j.virol.2008.06.004. Epub 2008 Jul 22.

8.

Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences.

Singh M, Krajewski M, Mikolajka A, Holak TA.

J Biol Chem. 2005 Nov 11;280(45):37868-76. Epub 2005 Aug 23.

9.

Kinetic recognition of the retinoblastoma tumor suppressor by a specific protein target.

Chemes LB, Sánchez IE, de Prat-Gay G.

J Mol Biol. 2011 Sep 16;412(2):267-84. doi: 10.1016/j.jmb.2011.07.015. Epub 2011 Jul 26.

PMID:
21787785
10.

Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor.

Todorovic B, Hung K, Massimi P, Avvakumov N, Dick FA, Shaw GS, Banks L, Mymryk JS.

J Virol. 2012 Dec;86(24):13313-23. doi: 10.1128/JVI.01637-12. Epub 2012 Sep 26.

11.
12.

Mapping the interactions of adenoviral E1A proteins with the p160 nuclear receptor coactivator binding domain of CBP.

Haberz P, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE.

Protein Sci. 2016 Dec;25(12):2256-2267. doi: 10.1002/pro.3059. Epub 2016 Oct 15.

13.

Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300.

Bernat A, Avvakumov N, Mymryk JS, Banks L.

Oncogene. 2003 Sep 11;22(39):7871-81.

PMID:
12970734
14.

Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.

Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, Garsky VM, Oliff A, Heimbrook DC.

Mol Cell Biol. 1993 Feb;13(2):953-60.

15.
16.

Comparison of the binding of the human papillomavirus type 16 and cottontail rabbit papillomavirus E7 proteins to the retinoblastoma gene product.

Haskell KM, Vuocolo GA, Defeo-Jones D, Jones RE, Ivey-Hoyle M.

J Gen Virol. 1993 Jan;74 ( Pt 1):115-9.

PMID:
8380832
17.

Modulation of allostery by protein intrinsic disorder.

Ferreon AC, Ferreon JC, Wright PE, Deniz AA.

Nature. 2013 Jun 20;498(7454):390-4. doi: 10.1038/nature12294.

18.
19.

E7 oncoprotein of human papillomavirus: Structural dynamics and inhibitor screening study.

Aarthy M, Kumar D, Giri R, Singh SK.

Gene. 2018 Jun 5;658:159-177. doi: 10.1016/j.gene.2018.03.026. Epub 2018 Mar 10.

PMID:
29535023
20.

Supplemental Content

Support Center